Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AclarionACON -2.55%31 Equity-to-Asset is 0.94 as of Jun. 2026, which is 54% above its 10-year median of 0.61. GuruFocus rates ACON with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Aclarion ranks better than 98.68% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aclarion's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $17.00 Mil. Aclarion's Total Assets for the quarter that ended in Jun. 2026 was $18.04 Mil.
Therefore, Aclarion's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.94.
The historical rank and industry rank for Aclarion's Equity-to-Asset or its related term are showing as below:
ACON'
s Equity-to-Asset Range Over the Past 10 Years
Min: -5.48 Med: 0.61 Max: 0.96
Current: 0.95
During the past 7 years, the highest Equity to Asset Ratio of Aclarion was 0.96. The lowest was -5.48. And the median was 0.61.
ACON's Equity-to-Asset is ranked better than 98.68% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 0.48
vs ACON: 0.95
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Aclarion Equity-to-Asset Related Terms
Aclarion Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Aclarion's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACON vs BRGX, VYND, VSEE: Equity-to-Asset Comparison
For the Health Information Services subindustry, Aclarion's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclarion Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Aclarion's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Aclarion's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Aclarion's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclarion (ACON) has a Equity-to-Asset of 0.94 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aclarion and its competitors. This is 54% above median its historical median of 0.61. According to the industry distribution chart, Aclarion ranks #9 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 1.3%.
Is Aclarion's Equity-to-Asset too high?
Aclarion's current Equity-to-Asset of 0.94 is 54% above median its 10-year median of 0.61. The Healthcare Providers & Services industry median Equity-to-Asset is 0.48. Aclarion's value of 0.94 is 95.8% above this industry median. Based on the distribution chart, Aclarion ranks #9 out of 683 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Aclarion has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Aclarion's Equity-to-Asset compare to BRGX and VYND?
According to the Healthcare Providers & Services industry distribution chart, Aclarion ranks #9 out of 683 companies for Equity-to-Asset. This places Aclarion in the top 1% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.48. Aclarion's value of 0.94 is 95.8% above this benchmark. While the company's 10-year median is 0.61 vs. the industry median of 0.48, Aclarion has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.48, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aclarion's current Equity-to-Asset of 0.94 is 95.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aclarion and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aclarion's current Equity-to-Asset is 0.94, which is 54% above median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclarion stock overvalued right now?
Aclarion (ACON) has a current Equity-to-Asset of 0.94. The current Equity-to-Asset is 0.94, which is 54% above median its 10-year median of 0.61 and 95.8% above the Healthcare Providers & Services industry median of 0.48. Aclarion's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Aclarion (ACON), the current Equity-to-Asset is 0.94 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
31GF Score
Get the complete analysis for ACON
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACON has been successfully added to your 
